WHO ICTRP trial
SIMPONI® to Arrest ß-cell Loss in Type 1 Diabetes
EUCTR2021-000189-13-Outside-EU/EEA · EU Clinical Trials Register
Key facts
| Trial ID | EUCTR2021-000189-13-Outside-EU/EEA |
|---|---|
| Public title | SIMPONI® to Arrest ß-cell Loss in Type 1 Diabetes |
| Scientific title | SIMPONI® to Arrest ß-cell Loss in Type 1 Diabetes |
| Primary sponsor | Janssen Biologics BV |
| Registry | EU Clinical Trials Register |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | United States |
| Conditions | SIMPONI® to Arrest ß-cell Loss in Type 1 Diabetes MedDRA version: 21.1 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Body processes… |
| Interventions | Trade Name: Simponi Product Name: Golimumab Product Code: CNTO148 Pharmaceutical Form: Solution for injection in pre-filled syringe INN or Proposed INN: GOLIMUMAB CAS Number: 476181-74-5 Current Sponsor code: CNTO148 Concentration unit: mg… |
| Registration date | Jan 14, 2021 |
| Secondary IDs | CNTO148DML2001 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: